Clinical trials: Metastatic Squamous Cell Carcinoma Neck
Oral Cancer, Lymph Node Metastasis
Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC
To evaluate the clinical outcomes of 2-year lymph node metastasis rate, disease-free survival, overall survival, and health-related quality of life in the patients with cT1N0M0 oral squamous cell carcinoma, who receive primary…
- Trial name
- NCT06623266
- Testing
- Neck management
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Huashan Hospital
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Head and Neck Squamous Cell Carcinoma
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the safety, tolerability and efficacy of intratumoral injections with an Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401) in patients with metastatic/recurrent HNSCC.
- Trial name
- NCT03433027
- Testing
- BB-401
- Where
- 6 sites in Australia, Russia
- Volunteers
- 16 people
- Sponsor
- Benitec Biopharma, Inc.
Targeted Therapy, HER2
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response rate (RR) determined by the Investigator using…
- Conditions
- Targeted Therapy, HER2, Biliary Tract Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT03185988
- Testing
- chemotherapy in combination with trastuzumab for arm1, chemotherapy in combination with trastuzumab for arm2, chemotherapy in combination with trastuzumab for arm3
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shen Lin
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Oral Cavity Squamous Cell Carcinoma
Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients.
Anti-cancer treatments have been thought to be closely related to their unique genetic alterations. In the past few years, the investigator have used cDNA microarray to delineate the transcriptome profiles of…
- Trial name
- CTC (NCT03917524)
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Cancer
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent or metastatic head and neck cancer.
- Trial name
- NCT00062387
- Testing
- perifosine
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This phase I/II trial studies the side effects of durvalumab, tremelimumab and hypofractionated radiation therapy in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread…
- Trial name
- NCT03522584
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Chemotherapeutic Agent Toxicity, Head and Neck Cancer
Randomized Amifostine For SCCHN
This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.
- Conditions
- Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity
- Trial name
- NCT00095927
- Testing
- Amifostine, Carboplatin, Paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative…
- Trial name
- NCT06935188
- Testing
- Dalpicilib combined with cetuximab, cetuximab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Effect of Drug
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
Pembrolizumab monotherapy and platinum-based chemotherapy in the combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been widely used in daily clinical practice based…
- Trial name
- NCT05252429
- Testing
- Docetaxel, Pembrolizumab
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Hokkaido University Hospital
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Squamous Cell Carcinoma of the Head and Neck
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck
The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient.
- Trial name
- COMMENCE (NCT02054442)
- Testing
- Cetuximab, Methotrexate
- Where
- 8 sites in Netherlands
- Volunteers
- 52 people
- Sponsor
- Radboud University Medical Center
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Head and Neck Cancer
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to…
- Trial name
- NCT00004070
- Testing
- IL-12
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute